Aurobindo Pharma (ARBN.BO): Maintain Sell; Near Term Growth Priced In, Risks Underappreciated

Research evidence excerpt

Aurobindo Pharma (ARBN.BO): Maintain Sell; Near Term Growth Priced In, Risks Underappreciated

Action |

09 Jul 2026 19:14:26 ET │ 14 pages

Aurobindo Pharma (ARBN.BO)

Maintain Sell; Near Term Growth Priced In, Risks Underappreciated

CITI'S TAKE

Aurobindo’s recent rally leaves stock trading at ~2SD above its 5-/10-year

mean and already discounting near-term earnings tailwinds from FX and

PLI benefits. We expect growth to moderate sharply in FY28–29E as Sell

pipeline visibility remains limited and sustaining volume-led growth on a Price (09 Jul 26 15:30) Rs1,580.45

high base becomes challenging. The benefits from Lannett could

disappoint, with sales down c30% as per IQVIA in the last one year while the Target price Rs1,270.00↑

growth levers like Biosimilars, Merck CMO are unlikely to fully offset from Rs1,020.00

pressure in the core generics. The company’s 2%/6% PAT CAGR over the Expected share price return -19.6%last 5/10 years, even from a low base, underscores limitations of its volume-

led business model. Trading at 20x FY28E EPS, ~30% above its historical Expected dividend yield 0.4%

average, valuations appear too stretched. Sell. Expected total return -19.3%

Market Cap Rs909,356M

FY26 decline highlights limit of volume led US growth — Auro’s US business was

US$9,641Mbroadly flat over FY21-26 and declined c7% in FY26, underscoring the limits of

volume-led growth in a structurally declining market. While management had earlier

highlighted injectables, peptides and inhalers as key value chain growth drivers,

execution has been mixed across these segments. The benefits from Lannett could

disappoint, with sales down c30% as per IQVIA. Price Performance

(RIC: ARBN.BO, BB: ARBP IN)

Limited near term upside from biosimilars/CMO — Auro’s near-term biosimilars in